Intravenous Infusions (XGHA:IIL) Long-Term Debt: GHS0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Long-Term Debt?

Intravenous Infusions XGHA:IIL +8.86% Long-Term Debt is GHS0.00 Mil as of . 20.

Intravenous Infusions's Long-Term Debt for the quarter that ended in . 20 was GHS0.00 Mil.

Intravenous Infusions  (XGHA:IIL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Intravenous Infusions Long-Term Debt Related Terms

Intravenous Infusions Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Long-Term Debt Chart

Intravenous Infusions Annual Data
Trend
Long-Term Debt

Intravenous Infusions Semi-Annual Data
Long-Term Debt
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Long-Term Debt of GHS0.00 Mil as of . 20.
Is Intravenous Infusions' Long-Term Debt too high?
Intravenous Infusions' current Long-Term Debt is GHS0.00 Mil.
How does Intravenous Infusions' Long-Term Debt compare to PTLF and PCYN?
Intravenous Infusions' Long-Term Debt of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Intravenous Infusions's current Long-Term Debt is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Long-Term Debt of GHS0.00 Mil. The current Long-Term Debt is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Long-Term Debt is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.